Several inhibitors of platelet aggregation have been shown to increase the intracellular level of cyclic AMP in other tissues either by stimulation of adenylate cyclase (PGE1, adenosine, and isoprenaline) or by inhibition of cyclic AMP phosphodiesterase (Robinson et al., 1971). The existence of a hormonally responsive adenylate cyclase in platelets has also been reported in vitro. The inhibitory effect of PGE1, adenosine, and isoprenaline has been shown to be associated with an increase of intracellular formation of cyclic AMP. This effect is greatly enhanced by the simultaneous addition of an inhibitor of cyclic AMP phosphodiesterase, like papaverine, theophylline, and pyrimido-pyrimidine compounds (Mills and Smith, 1972).
Adenosine Adrenaline PGE1 Theophylline Glucagon
This is a preview of subscription content, log in to check access
Mills, D.C.B., Smith, J.B.: The control of platelet responsiveness by agents that influence cyclic AMP metabolism. Ann. N.Y. Acad. Sci. 201, 291 (1972)CrossRefGoogle Scholar
Robinson, G.A., Butcher, R.W., Sutherland, E.W.: Cyclic AMP. New York and London: Academic Press 1971Google Scholar
Ryan, W.L., Durick, M.A.: Adenosine 3′-5′ monophosphate and N6–2′-O-dibutyryl-adenosine 3′-5′ monophosphate transport in cells. Science 177, 1002 (1972)PubMedCrossRefGoogle Scholar
Salzman, E.W., Levine, L.: Cyclic 3′-5′-adenosine monophosphate in human blood platelet II. Effects of N6 – 2′-O-dibutyryl cyclic 3′-5′-adenosine monophosphate on platelet function. J. clin. Invest. 50, 131 (1971)PubMedCrossRefGoogle Scholar
Song, Y., Cheung, W.Y.: Cyclic 3′-5′ nucleotide phosphodiesterase properties of the enzyme of human blood platelets. Biochem. biophys. Acta 242, 593 (1973)Google Scholar